key: cord-0295817-0y9fcyhb authors: Elliott, P.; Bodinier, B.; Eales, O.; Wang, H.; Haw, D.; Elliott, J.; Whitaker, M.; Jonnerby, J.; Tang, D.; Walters, C. E.; Atchinson, C.; Diggle, P. J.; Page, A. J.; Trotter, A.; Ashby, D.; Barclay, W.; Taylor, G.; Ward, H.; Darzi, A.; Cooke, G.; Chadeau-Hyam, M.; Donnelly, C. A. title: Rapid increase in Omicron infections in England during December 2021: REACT-1 study date: 2021-12-24 journal: nan DOI: 10.1101/2021.12.22.21268252 sha: 4d942fab48e66f22c97f701fad52794e5cf9911a doc_id: 295817 cord_uid: 0y9fcyhb The unprecedented rise in SARS-CoV-2 infections is concurrent with rapid spread of the Omicron variant in England and globally. We analysed prevalence of SARS-CoV-2 and its dynamics in England from end of November to mid-December 2021 among almost 100,000 participants from the REACT-1 study. Prevalence was high during December 2021 with rapid growth nationally and in London, and of the proportion of infections due to Omicron. We observed a large fall in swab positivity among mostly vaccinated older children (12-17 years) compared with unvaccinated younger children (5-11 years), and in adults who received a third vs. two doses of vaccine. Our results reiterate the importance of vaccination and booster campaigns; however, additional measures may be needed to control the rapid growth of the Omicron variant. evidence of a steep increase in prevalence in London with an estimated R of 1.62 (1.34, 1.93) from 1 December onwards and a daily prevalence reaching 6.07% (4.06%, 9.00%) on 14 December 2021. As of 1 to 11 December 2021, of the 275 lineages determined, 11 (4.0%) corresponded to the Omicron variant. The first Omicron infection was detected in London on 3 December, and subsequent infections mostly appeared in the South of England. The 11 Omicron cases were all aged 18 to 54 years, double-vaccinated (reflecting the large numbers of people who have received two doses of vaccine in this age group) but not boosted, 9 were men, 5 lived in London and 7 were symptomatic (5 with classic COVID-19 symptoms: loss or change of sense of smell or taste, fever, persistent cough), 2 were asymptomatic, and symptoms were unknown for 2 cases. The proportion of Omicron (vs Delta or Delta sub-lineages) was found to increase rapidly with a daily increase of 66.0% (32.7%, 127.3%) in the odds of Omicron (vs. Delta) infection, conditional on swab positivity. Highest prevalence of swab positivity by age was observed in (unvaccinated) children aged 5 to 11 years (4.74% [4.15%, 5 .40%]) similar to the prevalence observed at these ages in round 15. In contrast, prevalence in children aged 12 to 17 years more than halved from 5.35% (4.78%, 5.99%) in round 15 to 2.31% (1.91%, 2.80%) in round 16 . As of 14 December 2021, 76 .6% children at ages 12 to 17 years had received at least one vaccine dose; we estimated that vaccine effectiveness against infection was 57.9% (44.1%, 68.3%) in this age group. In addition, the prevalence of swab positivity in adults aged 65 years and over fell by over 40% from 0.84% (0.72%, 0.99%) in round 15 to 0.48% (0.39%,0.59%) in round 16 and for those aged 75 years and over it fell by two-thirds from 0.63% (0.48%,0.82%) to 0.21% (0.13%,0.32%). At these ages a high proportion of participants (>90%) had received a third vaccine dose; we estimated that adults having received a third vaccine dose had a three-to four-fold lower risk of testing positive compared to those who had received two doses. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 24, 2021. ; infections, may lead to renewed pressure on health services. Additional measures beyond vaccination may be needed to control the current wave of infections and prevent health services (in England and other countries) from being overwhelmed. The unprecedented rise in SARS-CoV-2 infections is concurrent with rapid spread of the Omicron variant in England and globally. We analysed prevalence of SARS-CoV-2 and its dynamics in England from end of November to mid-December 2021 among almost 100,000 participants from the REACT-1 study. Prevalence was high during December 2021 with rapid growth nationally and in London, and of the proportion of infections due to Omicron. We observed a large fall in swab positivity among mostly vaccinated older children (12-17 years) compared with unvaccinated younger children (5-11 years) , and in adults who received a third vs. two doses of vaccine. Our results reiterate the importance of vaccination and booster campaigns; however, additional measures may be needed to control the rapid growth of the Omicron variant. In many settings, vaccination against the SARS-CoV-2 virus has been shown to have reduced COVID-19-related hospital admissions and deaths [1, 2] . It has been estimated that vaccinations prevented 7.2 million infections and 27,000 deaths in England alone up to June 2021 [3] and could have prevented 163,000 deaths in the US between June and December 2021 [4] . However, the appearance of SARS-CoV-2 variants with increased transmissibility is an ongoing threat around the world [5, 6] . The recent emergence of the Omicron variant has led to travel restrictions, originally for those travelling from southern Africa, but recently for those wishing to travel from the UK. The Omicron variant has spread rapidly both in South Africa and in regions of the UK, driven by the ability of Omicron to cause more breakthrough infections among vaccinated individuals than other variants, likely due to the large number of genetic mutations within the viral spike protein [7] . Furthermore, vaccine-induced protection against the Delta variant (and its sub-lineages) was already found to be waning [8] . The REal-time Assessment of Community Transmission-1 (REACT-1) study [9] [10] [11] has been documenting the spread of the SARS-CoV-2 virus in England approximately monthly since May 2020 as the first wave of infections in England declined. REACT-1 charted the complete replacement of the Alpha variant by the Delta variant from round 12 (21 May to 7 June 2021) to round 13 (24 June to 12 July 2021) [11] . With round 16 (23 November to 14 December 2021) we are similarly able to document Omicron's early spread in England. In response to the pandemic, the national vaccination programme in England is evolving quickly. In September 2021 in addition to the vaccinations offered to those 16 years of age and over, school-aged children aged 12 to 15 years were offered a single dose of vaccine, and third (booster) doses were made available to health and social care workers, all those aged 50 years and over as well as younger people at risk. By December 2021, the opportunity to schedule booster doses has been extended to all adults (18 years of age and older) with heightened efforts to deliver the booster doses as quickly as possible. At the same time, there has been an accelerated rollout of the vaccination programme to older school-aged children (12 to 17 years) with double-doses now being offered to 12 to 15 year-olds as well as 16 and 17 year-olds [12] . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 24, 2021. ; Here we document the early detection of Omicron variant in England using the community-based REACT-1 study to avoid the biases that arise in case incidence data, including those arising to due test-seeking behaviour and limits on testing capacity [10] . We compare SARS-CoV-2 swab positivity in round 16 (23 November to 14 December 2021) to previous rounds and analyse vaccine effectiveness against infection in school-aged children aged 12 to 17 years and the effect of the third (booster) dose in adults (compared to those with with two doses) via linkage to National Health Service (NHS) vaccination data for consenting participants. In the sixteenth round of REACT-1, 803,864 randomly selected individuals aged 5 years and over in England were invited to take part in the study, with data collection from 23 Table 1 ). Fitting a P-spline regression model to all REACT-1 data, we found clear evidence for an increase in the weighted prevalence during round 16 starting around 1 December 2021 (Figure 1 A) . We estimated an overall reproduction number R=1. 13 (Table 1 ). Flexible P-spline models for three broad age groups also indicated an increasing prevalence in those aged 18 to 54 years (Figure 1 B ). is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 24, 2021. ; We found strong evidence of high and increasing weighted prevalence in London which had the highest weighted prevalence nationally at 1.84% (1.59%, 2.12%) compared with 1.23% (1.03%, 1.47%) in round 15 (Figure 2 A, Supplementary Daily estimates of weighted prevalence in each region separately show a steep increase in London from 0.80% (0.36%, 1.75%) on 26 November to 6.06% (4.06%, 9.00%) on 14 December (Figure 2 Assuming the dynamics of Omicron growth (and Delta's) remain constant, it is estimated to take 8.7 (5.4, 15.5) days for Omicron to increase from a proportion of 10% to 90%. This is approximately 3.5 times faster than the estimated 31.4 (43.9, 22.0) days it took for Delta to grow from 10% to 90% against Alpha. Assuming 100% sensitivity and a weighted prevalence 7 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 24, 2021. ; of 1.38% from 1 to 11 December 2021, during which the 11 Omicron variants were detected (out of 275 positives sequenced), we estimated a prevalence of Omicron infections in England of 31,000 (17,000, 55,000) averaged over that period, but at a time that prevalence was increasing rapidly. The 11 Omicron-infected participants were all aged 18 to 54 years, double-vaccinated (reflecting the large numbers of people who have received two doses of vaccine in this age group) and were not boosted, 9 (81.8%) were men, 5 (45.4%) lived in London and 7 (63.6%) were symptomatic: 5 (45.4%) reported classic COVID-19 symptoms (loss or change of sense of taste or smell, fever, persistent cough), 2 (18.2%) were asymptomatic, and symptoms were unknown for 2 cases. The highest weighted prevalence in round 16 by age was observed in those aged 5 to 11 years at 4.74% (4.15%, 5.40%) which was similar to that observed in round 15 at 4.76% is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 24, 2021. ; Our data also demonstrate the contribution of a third (booster) vaccine dose to the fall in prevalence we observed in round 16 in those aged 65 years and over. Over round 16, 91.2% and 96.8% of participants aged 65 to 74 years and 75 years and over, respectively, had received a third vaccine dose more than 14 days prior to swabbing (Supplementary Figure 1) . We estimated an adjusted odds ratio (OR) for swab positivity of 0.27 (0.22, 0.34) for adults aged 18 years and over who had received three vaccine doses compared to those having received two doses (Supplementary Table 6 ). We found highest weighted prevalence in round 16 in larger households including 5 people at 2.73% (2.25%, 3.32%) and 6 or more people at 2.65% (2.00%, 3.50%) compared to 0.88% (0.72%, 1.09%) in single-person households; in households with one or more children at 2.43% (2.23%, 2.65%) compared to 0.85% (0.76%, 0.95%) in households without children; in those having been in contact with a confirmed COVID-19 case at 8.00% (7.25%, 8.82%) compared to 0.81% (0.73%, 0.89%) for those without such contact, and in those reporting classic COVID-19 symptoms in the month prior to swabbing at 6.96% (6.32%, 7.67%) compared to 0.62% (0.55%, 0.70%) in those without symptoms (Supplementary Table 7) . Table 8 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 24, 2021. ; The sixteenth round of the REACT-1 study (23 November to 14 December 2021) followed a continuous period of high prevalence of SARS-CoV-2 in England from summer 2021 [11, 14] , TaqPath laboratories can be used as a proxy to monitor the spread of Omicron versus Delta [17] . In England, the first Omicron infection was recorded on 27 November and since then it has become the dominant variant, with 71.5% of samples having SGTF of those dated [18] [19] December 2021 and processed via TaqPath laboratories [18] . Based on these data, estimates of the regional doubling time for Omicron in England range from 1.6 to 2.5 days; London has the highest regional proportion of SGTF at 89.7%, followed by the East of England at 76.6% [18] . At the same time, the vaccine rollout in England has been accelerating to include a is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 24, 2021. ; times higher than that of Delta [6] , which may at least in part explain its transmission advantage. It has been suggested that Omicron may be associated with less severe disease than Delta with the caveat of differential population immunity from vaccination and previous infection [19] . However, the small number of Omicron infections observed in REACT-1 to date were among young to middle-aged adults where case fatality ratios will be lower than among the older population. Omicron may have greater escape from immunity conferred by vaccination than Delta, with an estimated 20 to 40 times higher antibody titre required for neutralisation [20] . based on SGTF [18] . However, these figures are likely underestimates, since they depend on people presenting for testing, and unlike community-based studies such as REACT-1, they do not include asymptomatic cases. As testing capacity becomes saturated by rising demand, there will be even greater need for estimates from community surveillance studies and a greater focus on hospitalisations as the epidemic progresses. Our findings in older school-aged children (12 years and over) amongst whom the vaccine programme (one and two doses) has been accelerated are encouraging. Since round 15 (19 October to 5 November 2021) we saw prevalence in this group drop by over a half, while it remained more or less unchanged amongst primary school-aged children (5 to 11 years). This strongly suggests that the vaccine programme, even a single dose, is effective at these ages. Accordingly, we report here estimates of vaccine effectiveness against infection 11 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 24, 2021. ; (assumed to be mainly Delta) of 55.7% for a single dose and 57.9% for one or two doses of vaccine. Our findings are similarly encouraging among older people (ages 65 years and over), most of whom have received a booster dose. In these age groups, prevalence from round 15 fell by over 40% at ages 65 to 74 years and by two-thirds among those aged 75 years and over. Our study has limitations. Our response rate was 12.1% (i.e. returned and valid tests compared with number of invitations), which, despite correction of our prevalence estimates using rim weighting [22] , may have introduced bias into our estimates. Our switch to postal from courier returns meant that some samples were obtained and posted after the nominated closing date; these samples were however processed in the usual way and the results included in our estimates. Although all positive samples on RT-PCR were sent for sequencing, reliable sequence data (at least 50% genome coverage) were obtained on around 60% of samples; with Omicron being first detected in our data for a sample collected on 3 December, our ability to monitor the spread of Omicron versus Delta lineages was limited by small numbers. Nonetheless we were able to detect the rapid increase in proportion of sequenced cases due to Omicron up to 11 December. Our estimates of vaccine effectiveness depend on comparability of the vaccinated and unvaccinated groups in all respects other than vaccination itself. For the school-aged children aged 12 years and over who were eligible for vaccination, the rollout was such that not all children were able to access vaccination at the same time making it more likely that vaccinated and unvaccinated children were similar in other respects. Likewise, in comparing double-vaccinated individuals with those having had a third (booster) dose, the assumption is that the two groups are similar other than their vaccine history. This assumption appears to be valid to the extent that to receive the booster dose, people will need to have been double-vaccinated. This is in contrast to comparisons between double-vaccinated and unvaccinated adults, where, in a highly vaccinated population, characteristics of the two groups are likely to be different [23] . The evidence to suggest that Omicron may cause less severe disease than Delta primarily originates in South Africa [19, 24] , where the population is comparatively younger than in England and where previous, very severe SARS-CoV-2 waves were driven by wild type, Beta 12 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 24, 2021. ; and Delta variants (rather than wild type, Alpha and Delta in England) [25] . Differences between populations and their rates of vaccination and previous infection might limit how much can be extrapolated from other settings such as South Africa to England. One indicative example is that during the week of 12-19 December, COVID-19 hospitalisations rose over 50% in London [26], a pattern not observed in areas with lower prevalence of Omicron. An increasing proportion of the population will have been vaccinated or experienced infection, and therefore may be less likely to have severe disease with Omicron infection compared to those who remain uninfected and not fully vaccinated. Even if infection with Omicron were less severe, the reduced risk of hospitalisation could be rapidly offset by its ongoing exponential growth in England. Close attention therefore needs to be paid to hospitalisation data in England (particularly in London) over the coming weeks, given the lag between infection and hospitalisation. In summary, we found strong evidence for the effectiveness of vaccination in adolescents and for booster vaccinations against infection in older populations, presumed to be mainly against the Delta variant in our data so far. However, Delta is rapidly being replaced in England by the Omicron variant and further data are needed to confirm the clinical relevance of the strong in vitro evidence of booster vaccines protecting against Omicron [7, 27] . Moreover, given that booster vaccines may take up to two weeks to have their full protective effect [28] , it is likely that a vaccination programme alone may not be sufficient to control the growth of Omicron in the short term. Additional measures beyond vaccination may be needed to control the current wave of infections and prevent health services (in England and other countries) from being overwhelmed. The REACT-1 study methods are published [9] . We have carried out cross-sectional surveys is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint invite a random sample in proportion to population size at LTLA level. This increased numbers sampled in densely populated urban areas while reducing the numbers in more rural areas. For both the original and revised sampling methods we used random iterative method (rim) weighting [22] correcting for age, sex, deciles of the IMD, LTLA counts, and ethnic group, to provide estimates that were representative of the population of England as a whole, as previously described [11] . From round 1 to round 13 (24 June to 12 July 2021) we used dry swabs which were collected from the participant's home by courier and then transported on a cold chain to a single laboratory. However, from round 14 we tested 'wet' (saline) swabs sent to the laboratory in a 1:1 randomised experiment either by courier (without cold chain) or by priority post [14] . Since both methods provided similar results, in subsequent rounds (15 and 16) swabs were returned only using the priority postal service. 14 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 24, 2021. ; However, the switch from courier to post for return of swabs meant that some samples were obtained after the nominated closing date for the study, to cover any delays in the postal service. Additional swabs received up to the cut-off date for laboratory analysis were included. We sent samples that tested positive to the Quadram Institute, Norwich, UK, for viral genome sequencing using the ARTIC protocol [31] (version 4) for viral RNA amplification and CoronaHiT for preparation of sequencing libraries [32] . We analysed sequencing data using the ARTIC bioinformatic pipeline[31] and assigned lineages using PangoLEARN (version 2021-11-4) [33]. We searched for Omicron defining mutations down to single reads. Data analyses were done using R software. We estimated weighted prevalence (and 95% credible intervals) of socio-demographic and other characteristics in round 16 and compared these to estimates from round 15. We then used logistic regression to estimate the effects of these variables on swab positivity with adjustment for age and sex, and also obtained mutually adjusted odds ratios (and 95% confidence intervals) for age, sex, region, employment type, ethnicity, household size, numbers of children in the household, neighborhood deprivation, and urban/rural environment. We investigated temporal trends in swab positivity using an exponential model of growth or decay with the assumption that numbers of positives out of the total number of samples per day arose from a binomial distribution. We used day of swabbing where reported, otherwise day of first scan of the sample by the Post Office (swabs were excluded from these analyses when neither date was available). We used a bivariate No-U-Turn Sampler with uniform prior for the probability of swab positivity on day of swabbing to estimate posterior credible intervals and the growth rate [34] . We estimated the reproduction number R by assuming a gamma-distributed generation time with shape parameter n=2.29 and rate parameter =0.36 (corresponding to a mean generation time of 6.29 days) [35] . 15 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 24, 2021. ; To visualise trends in swab positivity over time, we fit a Bayesian penalised-spline (P-spline) model [36] to the daily data using a No-U-Turn Sampler in logit space. We partitioned the data into approximately 5-day sections by regularly spaced knots, and minimized edge effects by adding further knots beyond the study period. We defined fourth-order basis splines (b-splines) over the knots and guarded against overfitting by including a second-order random-walk prior distribution on the coefficients of the b-splines, with the prior penalising against changes in the growth rate unless supported by the data, as previously described [11] . P-splines were also fit separately to three broad age groups (17 years and under, 18 to 54 years, 55 years and over) and to each region with a smoothing parameter obtained from the model fit to all the data. We fit a Bayesian logistic regression model to the proportion of lineages identified as the Omicron variant during round 16 to obtain a daily growth rate advantage for Omicron compared with Delta and its sub-lineages. We estimated geographical variation in prevalence at LTLA level, using a neighborhood spatial smoothing method based on nearest neighbor up to 30 km. We first obtained the median number of study participants in round 16 within 30 km of each study participant, and then calculated the local prevalence for 15 members of each LTLA to estimate the smoothed neighborhood prevalence in that area. We linked to data from the national COVID-19 vaccination programme to obtain information (with consent) on who had received one or more vaccinations and dates of vaccination. We is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 24, 2021. ; doses, allowing for a lag period of 14 days post-vaccination as above. Adjustments were made for age and sex, and, additionally, IMD, region and ethnicity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 24, 2021. ; Funding: The study was funded by the Department of Health and Social Care in England. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of this manuscript. is the author/funder, who has granted medRxiv a license to display the preprint in is the author/funder, who has granted medRxiv a license to display the preprint in is the author/funder, who has granted medRxiv a license to display the preprint in is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 24, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 24, 2021. ; Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant Effect of Vaccination on Household Transmission of SARS-CoV-2 in England COVID-19 vaccine surveillance report Week 25 COVID-19 preventable mortality and leading cause of death ranking -Peterson-KFF Health System Tracker Tracking SARS-CoV-2 variants SARS-CoV-2 variants of concern and variants under investigation in England: Technical Briefing 32. UK Health Security Agency Plasma neutralization properties of the SARS-CoV-2 Omicron variant Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months REal-time Assessment of Community Transmission (REACT) of SARS-CoV-2 virus: Study protocol Resurgence of SARS-CoV-2: Detection by community viral surveillance Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant NHS opens bookings for 12-15s to get second COVID jab Mapping income deprivation at a local authority level: 2019 -Office for National Statistics Breakthrough SARS-CoV-2 infections in double and triple vaccinated adults and single dose vaccine effectiveness among children in Autumn 2021 in England: REACT-1 study. Lancet Regional Medicine. doi:In Press 15. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern CoVariants [Internet SARS-CoV-2 variants of concern and variants under investigation in England Variant of concern: Omicron, VOC21NOV-01 (B.1.1.529) Technical briefing 30 Omicron daily overview: 21 Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa SARS-CoV-2 variants of concern and variants under investigation in England: Technical Briefing 31. UK Health Security Agency Booster of mRNA-1273 vaccine reduces SARS-CoV-2 Omicron escape from neutralizing antibodies Weighting survey results REACT-1 round 15 final report: Increased breakthrough SARS-CoV-2 infections among adults who had received two doses of vaccine, but booster doses and first doses in children are providing important protection Covid-19: Omicron is causing more infections but fewer hospital admissions than delta, South African data show Healthcare data: London mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant Effectiveness of BNT162b2 (Comirnaty, Pfizer-BioNTech) COVID-19 booster vaccine against covid-19 related symptoms in England: test negative case-control study 29. REACT 1 study materials 31. ncov2019-artic-nf: A Nextflow pipeline for running the ARTIC network's fieldbioinformatics tools pangolin: Software package for assigning SARS-CoV-2 genome sequences to global lineages. Github The no-U-Turn Sampler: Adaptively setting path lengths in Hamiltonian Monte Carlo How generation intervals shape the relationship between growth rates and reproductive numbers